Skip to main content
Clinical Trials/NCT02762019
NCT02762019
Completed
Phase 3

LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children

IRCCS Burlo Garofolo8 sites in 1 country101 target enrollmentSeptember 2013
ConditionsStomatitis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Stomatitis
Sponsor
IRCCS Burlo Garofolo
Enrollment
101
Locations
8
Primary Endpoint
Reduction of the grade of oral mucositis
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Children with cancer undergoing intensive chemotherapy (CT) regimens experience many side effects among which oral mucositis (OM) is one of the most debilitating. Modifications of CT's schedule and prolonged hospitalization may be necessary in presence of OM, causing poor general conditions and debilitation. Moreover, the use of narcotic analgesics and total parenteral nutrition may be required, triggering not only a physical deficit but also an economic burden. Despite the frequency and impact of OM among children with cancer, there is no consensus on standard therapy for this condition. Previous studies demonstrated that high power laser therapy can help the maintenance of nutritional status in patients with OM and can remarkably reduce costs/resources needed. Laser therapy has evidence of efficacy in reducing symptoms and in preventing the onset of OM in adult cancer patients but only one randomized controlled trial, with a limited number of children enrolled, supports its use in children for treatment of OM induced by chemotherapy.

This multicenter double-blind randomized controlled trial evaluates the efficacy of laser for treatment of oral mucositis secondary to chemotherapy in children aged 3-17 years.

The study involves 8 italian hospitals.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
October 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
IRCCS Burlo Garofolo
Responsible Party
Principal Investigator
Principal Investigator

Ronfani Luca

MD, PhD

IRCCS Burlo Garofolo

Eligibility Criteria

Inclusion Criteria

  • Children aged 3-18 years
  • Oral mucositis of grade 3 or 4 at enrollment (CTC - WHO scale)
  • Antiblastic chemotherapy in the in the previous three weeks
  • Willingness to undergo treatment for 4 consecutive days and to return for evaluation 7 and 11 days after enrollment.

Exclusion Criteria

  • Previous treatment with laser therapy for stomatitis
  • Presence of dysplastic oral lesions
  • Reduction of mouth opening (\<1 cm)
  • Localized head and/or neck radiation treatment in the previous 4 weeks
  • Use of keratinocyte growth factor (KGF)
  • Previous enrollment in the study

Outcomes

Primary Outcomes

Reduction of the grade of oral mucositis

Time Frame: 7 days after enrollment

Reduction of stomatitis' grade (from grade 3 or 4 to a lower grade). The grade of stomatitis is defined using the World Health Organization (WHO) evaluation scale

Secondary Outcomes

  • Reduction of pain, age 4-7 years(11 days after enrollment)
  • Reduction of need for analgesics(at day 7)
  • Reduction of the grade of oral mucositis(11 days after enrollment)
  • Reduction of pain, age 8-18 years(11 days after enrollment)
  • Adverse events(at day 11)

Study Sites (8)

Loading locations...

Similar Trials